Breast‐conserving surgery after neoadjuvant anthracycline‐based chemotherapy for large breast tumors
Open Access
- 18 August 2004
- Vol. 101 (5) , 918-925
- https://doi.org/10.1002/cncr.20491
Abstract
BACKGROUND: Randomized trials comparing neoadjuvant versus adjuvant chemotherapy show that primary chemotherapy allows more frequent breast‐preserving surgery even though no survival advantage has been demonstrated. The aim of the current study was to determine the predicting factors and the survival impact of breast conservation in patients with large breast tumors treated with neoadjuvant chemotherapy.METHODS: Between January 1987 and December 2001, 594 patients with invasive T2–3 breast carcinoma who were ineligible for breast‐conserving surgery (the mean initial tumor diameter was 49 mm) were treated with 3 or 4 courses of an anthracycline‐based primary chemotherapy, surgery, and radiotherapy. Various clinicopathologic factors were tested as possible predicting factors of breast‐preserving surgery. Survival analyses were performed to determine the implications of breast‐conserving surgery on outcome.RESULTS: After primary chemotherapy, 287 (48%) patients were eligible for breast‐conserving surgery and 307 patients underwent a mastectomy. Initial tumor diameter > 5 cm, low histologic grade, lobular histology, and multicentricity were independent predicting factors of breast conservation ineligibility in the multivariate analysis (logistic regression). In the univariate survival analysis, a failure of breast‐preserving surgery was associated with a poor outcome. Local disease recurrence‐free survival rates were similar in patients treated with lumpectomy and mastectomy.CONCLUSIONS: The results reported in the current study suggested that initial diameter, histologic type and grade, and multicentricity are potential prechemotherapy predicting factors of breast conservation. When carefully selected, patients treated with breast conservation had a risk of local disease recurrence similar to the risk of chest wall disease recurrence after mastectomy. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 31 references indexed in Scilit:
- Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinomaEuropean Journal of Surgical Oncology, 2003
- Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast CarcinomaAnnals of Surgery, 2002
- A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibilityAnnals of Surgical Oncology, 2002
- Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapyEuropean Radiology, 2002
- Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breastEuropean Journal of Surgical Oncology, 2001
- Preoperative/neoadjuvant medical therapy for early breast cancerThe Lancet Oncology, 2001
- Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imagingCancer, 1996
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990
- Conservative treatment of early breast cancer: Prognostic value of the ductal in situ component and other pathological variables on local control and survivalEuropean Journal of Cancer and Clinical Oncology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958